Dexcom (DXCM)
NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
$73.57+1.64%
Close 2026-07-07 · 1-day change
Reading DXCM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DXCM free→NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
Reading DXCM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DXCM free→QuarterlyIQ Insights · DXCM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
OTHER EVENTS. On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2027 (the “Share Repurchase Program”). In connection with the approval of the Share Repurchase Program, the Board of Directors terminated its existing share repurchase program, of which $250.0 million remained…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On April 30, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Chief Executive Officer — Kevin R. Sayer: Kevin R. Sayer is retiring as CEO and transitioning to Executive Chairman.
Director — Albert F. Osterloh, IV: DexCom appointed Albert F. Osterloh, IV as a new director and to serve on the Compensation Committee and Technology Committee.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 12, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. In connection with remarks to be made at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, beginning at 10:30 a.m. (Eastern Time), DexCom, Inc. (“Dexcom”) President and Chief Executive Officer, Jake Leach, will report preliminary, unaudited financial results for the fourth quarter of 2025 and fiscal year 2025, initial financial outlook for fiscal year 2026, and certain other information. The fourth quarter and fiscal…
President and Chief Executive Officer — Jacob S. Leach: Jacob S. Leach was promoted to President and CEO, succeeding Kevin R. Sayer.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 30, 2025, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
Director — Dr. Euan Ashley: DexCom appointed Dr. Euan Ashley as a director and to the Nominating and Governance Committee and Technology Committee.
Chief Executive Officer and Chairman of the Board — Kevin R. Sayer: Kevin R. Sayer is taking a temporary medical leave of absence.
CEO — Kevin R. Sayer: Kevin R. Sayer is retiring as CEO and being succeeded by Jacob S. Leach.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On July 30, 2025, DexCom, Inc. (“Dexcom” or the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025, the management changes described below, and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securitie…
President and Chief Operating Officer — Jacob S. Leach: Jacob S. Leach was promoted to President and Chief Operating Officer with a raise in salary and eligibility for an annual cash performance bonus.
Director and Committee Member — Renée Galá: Ms. Renée Galá was appointed to serve on the Audit Committee and Compensation Committee of the Board.
The filing pertains to stockholder approval of equity incentive and employee stock purchase plans, as well as a decrease in the board size.
Director — Karen Dahut: Karen Dahut resigned from the Board of Directors.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On May 1, 2025, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended March 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…
OTHER EVENTS. On May 1, 2025, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $750.0 million of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2026 (the “Share Repurchase Program”). Repurchases of Common Stock under the Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods,…
of Form 8-K dated March 21, 2025, of DexCom, Inc. and are in agreement with the statements contained in the first paragraph insofar as related to the date of notification of our dismissal as the Company’s independent registered public accounting firm and in the second through fourth paragraphs therein. We have no basis to agree or disagree with other statements of the registrant contained therein. /s/ Ernst & Young LLP
Director — Renée Galá: Renée Galá was appointed as a new director to the Board of Directors.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 13, 2025, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. In connection with remarks to be made at the J.P. Morgan 43rd Annual Healthcare Conference on Monday, January 13, 2025, beginning at 12:00 p.m. (Eastern Time), DexCom, Inc. (“Dexcom”) Chairman, President and Chief Executive Officer, Kevin Sayer, will report preliminary, unaudited financial results for the fourth quarter of 2024 and fiscal year 2024, initial financial outlook for fiscal year 2025, and certain other information. The fourth quarter…
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. As previously disclosed, DexCom, Inc. (the “Company”) has been involved in global patent litigation with Abbott Diabetes Care, Inc. (“Abbott”) and its affiliates. Both the Company and Abbott have accused the other of infringing certain patents, and each party has filed counterclaims and actions to invalidate the other party’s patents. On December 20, 2024, the Company and Abbott entered into a settlement and patent cross license agreement (the “Agre…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 24, 2024, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended September 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On July 25, 2024, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended June 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.